Orthofix Medical Inc.
NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
セクター: Healthcare
業種: Medical - Devices
上場日: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
連絡先情報
時価総額
$469.69M
PER (TTM)
-5.1
26.6
配当利回り
--
52週高値
$17.00
52週安値
$10.24
52週レンジ
順位38Top 36.9%
4.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$219.91M+0.00%
直近4四半期の推移
EPS
-$0.06+0.00%
直近4四半期の推移
フリーCF
$17.61M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Net Sales Growth Achieved Total net sales reached $822.3M, reporting 2.9% growth; constant currency growth was 2.4% for the year.
Gross Margin Expansion Gross Margin improved 0.5 points to 68.8%; Net Loss narrowed by $33.8M compared to the prior year results.
Limb Reconstruction Sales Rise Global Limb Reconstruction sales increased 8.4% reported to $134.7M; U.S. growth led at 15.8% driven by investments.
R&D Spending Reduced Research and development expense decreased 10.6% to $65.8M following strategic discontinuation of M6 product lines.
リスク要因
Healthcare Industry Consolidation Industry consolidation pressures pricing; GPOs/IDNs may exclude suppliers, materially affecting profitability and market access.
Integration of SeaSpine Merger Continued SeaSpine integration poses risk; failure to achieve intended synergies may adversely affect operating efficiencies and cost savings goals.
Pending Litigation Exposure Multiple litigation and arbitration matters pending, including former executives; accrual of $18.3M reflects ongoing financial uncertainty.
Regulatory Compliance Costs Extensive global regulation, especially E.U. MDR, requires significant ongoing costs to maintain compliance and market access.
見通し
Focus on Profitable Growth Discontinuing M6 product lines to allocate resources toward more profitable growth opportunities across Global Spine segment.
Digital Platform Leverage Limb Reconstruction strategy emphasizes leveraging OrthoNext digital platform for planning and improving surgical outcomes.
Spine Technology Development Future growth driven by internally developed technologies and external acquisitions, focusing on cervical and thoracolumbar anatomy.
Liquidity Management Intend to retain consolidated earnings to finance continued growth; currently compliant with $15.0M unrestricted cash covenant.
同業比較
売上高 (TTM)
$854.40M
$822.31M
$701.20M
粗利益率 (最新四半期)
100.0%
91.0%
83.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| MLTX | $1.23B | -4.9 | -67.1% | 17.8% |
| SVRA | $1.07B | -9.8 | -84.0% | 11.8% |
| BFLY | $967.60M | -12.5 | -35.3% | 6.9% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.3%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし